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ABSTRACT  
Vibrating mesh nebulizers (VMN) demonstrate improved efficiency for delivery of inhaled aerosol solutions or suspensions as c ompared to 
compressor devices. The added advantages of compactness, portability and functioning as noise-free device makes them of incremental value in 
Home or Ambulatory settings while managing Severe Obstructive airway disease or delivery of maintenance medications in these cases. This 
further circumvents the need for multiple devices thereby further improving patient compliance and convenience while delivering acute or 
maintenance formulations including Glycopyrronium (GLY) and Formoterol (FRM)/Budesonide(BUD) nebulizing solution formulations . To 
further assess the clinical role and feasibility of FRM-BUD formulation delivery kinetics  with or without GLY nebulizing solution through VMN 
and jet  nebulizers for In- & outpatient settings, 2 comparative in-vitro lung deposition studies were carried out utilizing Anderson Cascade 
impactor at 30 L/min; with deposited drug estimated by HPLC. Post-hoc analyses with p<0.05 were considered statistically significant for 
intergroup differences on FRM/BUD and GLY delivered through VMN or Compressor devices.  The calculated mean fine particle dose for FRM & 
BUD delivered by VMN or jet nebulizer showed no statistical difference. However the mean fine particle fraction for BUD delivered by VMN was 
significantly better compared to jet nebulizer. The Residual volume at 10 mins was significantly higher with jet nebulizer. The optimal 
Aerodynamic Particle Size Distribution (APSD) for GLY nebulizing solution admixture with FRM/BUD suspension delivered through VMN and 
Jet nebulizer offers a clinically relevant strategy for High risk COPD cases in Acute or Home settings. 
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INTRODUCTION 
India has growing burden of chronic respiratory diseases 
including Bronchial asthma, asthma-COPD overlap (ACO) 
and COPD that are an important contributor towards deaths 
and disability adjusted life years (DALYs).  
The contribution of chronic respiratory diseases to the total 
DALYs in India increased from 4·50.4%in 1990 to 
6·40.6%in 2016. Of the total DALYs due to chronic 
respiratory diseases in India, COPD and asthma account for 
75·6% and 20·0% respectively1. 
Recent studies of peak inspiratory flow after recovery from 
an acute exacerbation found that 19%–52% of COPD patients 
had insufficient peak inspiratory flow for effective DPI use, 
and those patients were more likely to be older and have 
more severe disease2. In most of these cases (ie. GOLD D), the 
administration of ICS/LABA and LAMA remains a clinical 
challenge with the conventional devices with almost one-
third of the post-discharge cases having low peak inspiratory 
flow rate (PIFR) of ≈30% l/min following a severe 
exacerbation. However in case of a differential diagnosis 
involving clinical symptomatology of ACO, baseline therapy 
of ICS/LABA with LAMA is again recommended3. In either of 
these cases, education, adherence and review of patient 
inhalation technique in the post-discharge phase remains 
critical for optimizing health outcomes especially with 
conventional devices.  
A systematic review found that 45% of pMDI users had 
suboptimal hand-breath coordination for optimal drug 
delivery. Coordination limitations can be addressed by the 
Menon et al                                                                                                                    Journal of Drug Delivery & Therapeutics. 2019; 9(6):79-82 
ISSN: 2250-1177                                                                                  [80]                                                                                 CODEN (USA): JDDTAO 
use of holding chambers or spacers; however, errors in 
handling, execution, and breath holding technique are still 
common4,5. 
The mainstay of treatment involves delivery of rescue and 
maintenance therapies through a compressor air (jet) 
nebuliser along with short course therapy with steroids and 
antibiotics. Compressor air nebulizers  commonly used in 
hospitals require a compressor or pressurized gas source to 
operate, and tend to be inefficient, leaving up to 1.4mL of 
medication in the reservoir at end of dose. To overcome the 
limitations of compressor air nebulizers, several new 
nebulizer technologies, such as active vibrating mesh 
nebulizers (VMN), have been developed. The VMN is 
electronically operated, requiring no gas to generate aerosol, 
with greater efficiency associated with low residual drug 
volume at end of nebulization ( < 0.1 mL)6-8. while delivering 
rescue or maintenance nebulizing solutions including 
ICS/LABA and/or anticholinergics.  
Glycopyrronium and Formoterol/Budesonide nebulizing 
formulations have been available as Maintenance therapy for 
the management of obstructive airway diseases and related 
phenotypes including ACO9. Combination of these drug 
solutions or suspensions in the nebulizer for simultaneous 
nebulization remains a pertinent strategy in clinical 
practice10. However, little information is available on the 
compatibility of drugs when admixed for the effect on 
particle size distribution and aerosol output  
To further assess the clinical role and feasibility of 
Formoterol/ Budesonide formulation delivery kinetics with 
and without combination with Glycopyrronium formulation 
through VMN and Compressor air nebulizers for In- & 
outpatient settings, two comparative in vitro lung deposition 
studies were carried out utilizing Anderson Cascade 
impactor  
MATERIAL AND METHODS 
The in vitro Lung deposition studies were carried out using 
Anderson Cascade impactor (ACI) at 30 L/min using 
Nebulizing formulations of Glycopyrronium (25 mcg/2 ml) 
and Formoterol/Budesonide (20 /500 mcg) provided by 
Glenmark Pharmaceuticals Ltd.  
The ACI study was carried out for the assessment of the 
aerodynamic properties of the above mentioned products for 
nebulization using both the nebulizers, i.e. jet and the 
vibrating mesh types. Inspiratory flow rate of 30L/min was 
used as per manufacturer’s specifications (Copley 
Scientific).ACI was assembled with glass fiber filter and 
stages (S-0, S1, S2, S3, S4, S5, S6, S7). 
Formoterol/Budesonide smartule 20/500 mcg/ 2 ml for 
Study I and Formoterol/Budesonide smartule 20/500  mcg/ 
2 ml & Glycopyrronium nebulizing solution 25mcg/ 2ml for 
Study II were opened and the contents placed in nebulizer 
medication chamber. For Compressor air nebulizer, the 
smartule content were diluted with distilled water. The 
length of the time interval for nebulization for each device 
was decided based on the time required for the delivery of 
volume of MilliQ water equivalent to the volume of contents 
of the smartule and the diluent for the corresponding 
nebulizer device, ensuring the sufficient amount of drug to 
be delivered in the ACI assembly for the purpose of 
quantification. Apparatus was dismantled and each stage and 
filter were carefully washed with suitable solvent (diluent- 
Methanol AR: MilliQ water in 60:40 ratio) and washings 
collected into a beaker (Volume of the solvent used: 25 ml for 
Device and induction port washings and 10 ml for remaining 
stages). Active substance at each stage (deposition) was 
determined by using developed reverse phase gradient HPLC 
method of analysis.  
The recovered active substance deposition from each stage 
of the cascade impactor was processed in the CITDAS 
software provided by Copley Scientific Ltd. UK. The 
characteristics of the aerosol were determined and assessed 
using several parameters including fine particle fraction 
(FPF), MMAD, and fine particle dose (FPD). The definitions 
included FPF: Fraction of the aerosol that is in a size range 
with the potential of the fine particle (<5 µ) dose divided by 
the total delivered dose; MMAD: Diameter of drug particles 
at which 50% of particles by mass is larger and 50% are 
smaller; FPD is the quantity of drug with fine particle size 
and related to drug deposition in the lung,[4-6] 
RESULTS 
In vitro Lung deposition was characterized by FPD, FPF, 
MMAD, Nebulization time & Residual volume for 
Formoterol/Budesonide & Glycopyrronium nebulizing 
suspension delivered by VMN or Compressor air nebulizer in 
both the studies.  (Tables 1, 2) 
In Study I, the calculated mean FPD for Formoterol & 
Budesonide delivered by VMN or Compressor air nebulizer 
showed no statistical difference (p= 0.19 & p=0.15 
respectively). Similarly, the mean FPF for Formoterol was 
again comparable in both the arms (p= NS) with incremental 
impact on Budesonide delivery by VMN that was significantly 
better compared to Compressor air nebulizer (p=0.04). The 
Residual volume at 10 mins was significantly higher with 
Compressor air nebulizer (0.5 ml). 
  
Table 1: Study I, in vitro Lung deposition study results using ACI with VMN & Compressor air nebulizer for Formoterol/ 
Budesonide nebulizing suspension 
Sr. 
no.  
Parameter Vibrating Mesh Nebulizer Compressor Air Nebulizer 
Formoterol Budesonide Formoterol Budesonide 
1 FPD 11.93.0* 183.263* 7.30.2 71.111.2 
2 FPF 68.48.6* 62.25.03# 59.71.6 45.52.2 
3 MMAD 3.70.5* 4.30.2# 4.50.1 50.1 
4 Residual Volume Negligible 0.5 ml 
*p=NS vs Compressor air nebulizer; #p<0.05 vs. Compressor air nebulizer.      
FPD: Fine Particulate Dose (<5);     FPF: Fine Particle Fraction (% Drug <5);    MMAD: Median mass aerodynamic diameter 
 
The second study (Study II) explored for the first time the 
clinical feasibility of Glycopyrronium solution admixture 
with Formoterol/Budesonide formulation assessing the 
APSD or delivery kinetics in real world outpatient settings of 
India. In case of formoterol Fumarate, glycopyrronium and 
budesonide there is no statistically significant difference 
observed in MMAD, FPD, and FPF between two nebulizer 
devices.
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Table 2: Study II, In vitro Lung deposition study results using ACI with VMN & Compressor air nebulizer for 
Formoterol/ Budesonide nebulizing suspension in combination with Glycopyrronium nebulizing solution 
S.
N. 
Parameter Vibrating Mesh Nebulizer Compressor Air Nebulizer 
Formoterol Budesonide Glyco-
pyrronium 
Formoterol Budesonide Glyco-
pyrronium 
1 FPD 10.59 ± 4.08* 139.21 ± 67.58* 15.22 ± 7.34* 7.06 ± 2.52 116.14 ± 65.65 14.99 ± 9.03 
2 FPF 48. 88 ± 6.74* 43.77 ± 13.16* 54.44 ± 10.26* 45.34 ± 14.12 42.94 ± 6.06 57.19 ± 14.37 
3 MMAD 4.97 ± 0.67* 5.1 ± 0.75* 4.44 ± 1.06* 5.1 ± 0.66 5.2 ± 0.26 4.4 ± 1.22 
4 Residual 
Volume 
Negligible 0.12 ml 
*p=NS vs Compressor air nebulizer; #p<0.05 vs. Compressor air nebulizer   
FPD: Fine Particulate Dose (<5);      FPF: Fine Particle Fraction (% Drug <5);     MMAD: Median mass aerodynamic diameter 
 
DISCUSSION 
This is the first study to assess the pharmacokinetic 
compatibility and delivery kinetics for Formoterol/ 
Budesonide with or without Glycopyrronium nebulizing 
formulations when admixed at the same time for delivery 
with Active vibrating mesh and compressor air nebulizer. 
The only publications till date by Akapo11 and Kamin12 
suggest the likely compatibility of above formulations as 
admixture with no further evidence on the clinical impact or 
in vitro lung deposition or APSD assessments. These results 
have likely impact on the clinical role of Home nebulization 
for delivery of Rescue or Maintenance therapies particularly 
in High risk COPD cases while preventing 30-day 
readmission or 1-yr mortality that is quite common in such 
cases13,14 due to varying reasons including nonadherence or 
suboptimal utilization of the conventional devices. 
In this line Home nebulization with the conventional 
compressor air nebulizers are often considered 
cumbersome, bulky, noisy for delivery of rescue and 
maintenance therapies especially for ambulatory patients. 
Literature review suggests bacterial contamination of 
nebulizers used by patients has often been described15. Even 
in most developed countries, an investigation of different 
components of nebulizer systems used at home showed that 
50% of these components were contaminated16. The new 
generation, handy, portable, noise-free vibrating mesh 
nebulizers offer minimal intervention with regular hygiene 
of the medication cup on every use  
The results of the current studies with active VMN the mean 
values for fine particle dose (FPD) and Fine particle fraction 
(FPF) from APSD testing are well within the specified limits 
including 85 to 115% of the emitted dose from the 
compressor air nebulizer17.The results are also comparable 
to the APSD testing and results for Glycopyrronium 
nebulizing solution tested for delivery with eFLOW*Closed 
System nebulizer that is available in the international 
market18,19. 
The observed results for FPF (50%) ensures optimal 
efficiency with active VMN and compressor air nebulizer for 
delivery of Nebulizing Suspension/s during acute 
exacerbation or maintenance therapy in stable cases. 
Negligible residual volume with zero dilution factor further 
complements the clinical rationality and utility of active VMN 
for Home nebulization for delivery of rescue or maintenance 
medications. 
The results need to be further evaluated in large pivotal 
clinical trials to further assess the clinical impact of the dual 
or triple drug combination aerosol delivery kinetics or lung 
deposition on clinical endpoints in High risk COPD cases as 
maintenance therapy. Although both CEN and USP [601] 
recommend the aerosol characterization for nebulizing 
formulations with 15L/min flow rate, the results with the 
current study are incremental in mimicking the real world 
practice of pMDI or VMN attachment to proximal arm of non-
invasive ventilation (NIV) that may hamper the smooth 
inhalation of the Soft mist generated subsequently for 
adequate inhalation in such cases on BiPAP or IPAP/EPAP 
airflow maneuvers20,21. 
The current study was therefore conducted using ACI at 30 
L/min, (Copley Scientific), patients of AECOPD during acute 
or post discharge phase of moderate or severe 
exacerbation21,22. 
CONCLUSION 
 The optimal APSD for Glycopyrronium nebulizing solution 
admixture with Formoterol/Budesonide suspension 
delivered through VMN and Compressor air nebulizer offers 
a clinically relevant strategy for High risk COPD cases in 
Acute or Home settings  
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